Communal Non-Profit Enterprise Regional Center of Oncology | Kharkiv, Ukraine

Research site

(Unclaimed)

Location

4, Lisoparkivska, str., Kharkiv, Kharkiv, Ukraine

Site insights

Top conditions

Top treatments

Veliparib

Paclitaxel

Carboplatin

TAK-788

Platinum

docetaxel

Eculizumab

Ruxolitinib

Pomalidomide

Tafasitamab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 18 total trials

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rit...

Active, not recruiting

Marginal Zone Lymphoma

Follicular Lymphoma

Drug: tafasitamab

Drug: placebo

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...

Active, not recruiting

Multiple Myeloma

Drug: Pomalidomide

Drug: Venetoclax

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01)

This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzum...

Active, not recruiting

Gastroesophageal Adenocarcinoma

Gastric Neoplasms

Drug: Tislelizumab

Drug: Capecitabine

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

The purpose of this research study is to determine the safety and tolerability of TL-895. There are 2 parts of this study. Part 1 tested increasing d...

Active, not recruiting

Relapsed/Refractory B Cell Malignancies

Treatment-Naive B Cell Malignancies

Drug: Navtemadlin

Drug: TL-895